Trial Profile

A Randomised, Double-blind, Placebo-controlled Proof-of-pharmacology Study of EP395 in Healthy Adults

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 16 Jun 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EP 395 (Primary)
Indications Chronic obstructive pulmonary disease; Respiratory tract disorders
Focus Pharmacodynamics; Proof of concept
Sponsors EpiEndo Pharmaceuticals

Most Recent Events

11 Jun 2025 According to EpiEndo Pharmaceuticals media release,data from this trial published in Pulmonary Pharmacology and Therapeutics.
22 Jun 2023 Status changed from recruiting to completed.
30 Sep 2022 Planned End Date changed from 1 Apr 2023 to 1 May 2023.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com